Product Information
TOPIRAMATE ER 150 MG SPRINK CAP is a generic product labeled by Zydus Pharmaceuticals (USA) Inc., priced at $7.3569 per EA under NDC 70710104203. Its NADAC has been published 182 times since Apr 12, 2023.
FDA first approved this application on Nov 29, 2022. Its Orange Book therapeutic-equivalence code is AB2 — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
150 mg/1
Manufacturer
Zydus Pharmaceuticals (USA) Inc.NDC
70710104203
Classification
Generic
Dosage Form
CAPSULE, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
TOPIRAMATEApproval Type
Generic (ANDA)
FDA Application
ANDA208949FDA Approved
11/29/2022
TE Code
AB2
On Market Since
1/17/2023
Pharmacological Classes
Price Statistics
The NADAC for TOPIRAMATE ER 150 MG SPRINK CAP has been published 182 times since Apr 12, 2023, and over the history we have for it it has declined 51.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.3569 per EA |
|---|---|
| All-time high | $16.7776 (Mar 13, 2024) |
| All-time low | $7.3569 (Sep 23, 2026) |
| 52-week high | $11.9736 |
| 52-week low | $7.3569 |
| Median price | $11.4951 |
| Average price | $12.3736 |
| Largest weekly change | +54.2% (Oct 18, 2023) |
| Weeks tracked | 182 |
| Tracking since | Apr 12, 2023 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). None of the shown alternatives sit below the current price. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Zydus Pharmaceuticals (USA) Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Topiramate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of TOPIRAMATE ER 150 MG SPRINK CAP?
The current National Average Drug Acquisition Cost (NADAC) for TOPIRAMATE ER 150 MG SPRINK CAP, manufactured by Zydus Pharmaceuticals (USA) Inc., is $7.3569 per EA (NDC 70710104203), effective Sep 30, 2026.
How has the price of TOPIRAMATE ER 150 MG SPRINK CAP changed over time?
Over the history we have for it, the NADAC for TOPIRAMATE ER 150 MG SPRINK CAP has declined 51.2%. It has been tracked across 182 weekly CMS publications since Apr 12, 2023.
What are the highest and lowest recorded NADAC prices for TOPIRAMATE ER 150 MG SPRINK CAP?
Since Apr 12, 2023, the NADAC for TOPIRAMATE ER 150 MG SPRINK CAP has ranged from a low of $7.3569 (Sep 23, 2026) to a high of $16.7776 (Mar 13, 2024), with a median of $11.4951 per EA.
Are there cheaper alternatives to TOPIRAMATE ER 150 MG SPRINK CAP?
2 manufacturers publish a NADAC-priced product with the same active ingredient and strength as TOPIRAMATE ER 150 MG SPRINK CAP in a comparable dosage form, but none are currently priced below it.
Who manufactures TOPIRAMATE ER 150 MG SPRINK CAP?
TOPIRAMATE ER 150 MG SPRINK CAP (NDC 70710104203) is labeled by Zydus Pharmaceuticals (USA) Inc., and CMS classifies it as a generic product.